Revolution Medicines Presents Overall Survival Data for RASONQUE™ (daraxonrasib) Across Subgroups in Previously Treated Metastatic Pancreatic Cancer at ESMO 2026GlobeNewsWire · 2 days ago
Revolution Medicines to Report Financial Results for Third Quarter 2026 After Market Close on November 4, 2026GlobeNewsWire · 3 days ago
Revolution Medicines Begins Phase 3 Trial For Advanced Lung Cancer TreatmentBenzinga · 4 days ago
Revolution Medicines Begins Treating Patients in Phase 3 RASolve 308 Trial Evaluating Zoldonrasib in Combination with Pembrolizumab and Chemotherapy as First-Line Treatment for Patients with Metastatic RAS G12D Non-Squamous Non-Small Cell Lung CancerGlobeNewsWire · 5 days ago
7,403 Shares in Revolution Medicines, Inc. $RVMD Purchased by SteelPeak Wealth LLCDefense World · 6 days ago
3,373 Shares of Revolution Medicines, Inc. $RVMD Bought by First Citizens Bank & Trust Co.Defense World · Oct 17, 2026Revolution Medicines, Inc. is a precision oncology firm operating in the clinical development stage, dedicated to creating innovative treatments that target novel pathways crucial for RAS-driven cancers. Its pipeline includes several promising drug candidates: RMC-4630, an SHP2 inhibitor, is currently undergoing Phase 1/2 clinical trials for various solid tumors, such as gynecological and colorectal cancers. The company's portfolio also features RMC-5845, a selective inhibitor designed to target SOS1, a protein responsible for activating RAS within cells, and RMC-5552, a highly selective inhibitor for hyperactive mTORC1 signaling found in cancerous cells.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 5, 2026 | -$2.04 | -$3.06 | Miss |
| May 6, 2026 | -$1.84 | -$2.29 | Miss |
| Feb 25, 2026 | -$1.58 | -$1.86 | Miss |
| Nov 5, 2025 | -$1.42 | -$1.61 | Miss |
| Aug 6, 2025 | -$1.14 | -$1.31 | Miss |
| May 7, 2025 | -$1.12 | -$1.13 | Miss |